CDK9 inhibitors have a significant inhibitory effect on acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) (Yin et al., 2014; Boffo et al., 2018). The gene discussed is CDK9; the disease is B-cell chronic lymphocytic leukemia.